Abstract:Senescence refers to a cellular state featuring a stable cell‐cycle arrest triggered in response to stress. This response also involves other distinct morphological and intracellular changes including alterations in gene expression and epigenetic modifications, elevated macromolecular damage, metabolism deregulation, and a complex proinflammatory secretory phenotype. The initial demonstration of oncogene‐induced senescence in vitro established senescence as an important tumour suppressive mechanism, in addition to apoptosis. Senescence not only halts the proliferation of premalignant cells but also facilitates the clearance of affected cells through immunosurveillance. Failure to clear senescent cells owing to deficient immunosurveillance may, however, lead to a state of chronic inflammation that nurtures a pro‐tumorigenic microenvironment favouring cancer initiation, migration, and metastasis. In addition, senescence is a response to post‐therapy genotoxic stress. Therefore, tracking the emergence of senescent cells becomes pivotal to detect potential pro‐tumorigenic events. Current protocols for the in vivo detection of senescence require the analysis of fixed or deep‐frozen tissues, despite a significant clinical need for real‐time bioimaging methods. Accuracy and efficiency of senescence detection is further hampered by a lack of universal and more specific senescence biomarkers. Recently, in an attempt to overcome these hurdles, an assortment of detection tools have been developed. These strategies all have significant potential for clinical utilization, and include flow cytometry combined with histo‐ or cytochemical approaches, nanoparticle‐based targeted delivery of imaging contrast agents, OFF‐ON fluorescent senoprobes, positron emission tomography (PET) senoprobes, and analysis of circulating SASP factors, extracellular vesicles, and cell‐free nucleic acids isolated from plasma. Here we highlight the occurrence of senescence in neoplasia and advanced tumours, assess the impact of senescence on tumorigenesis, and discuss how the ongoing development of senescence detection tools might improve early detection of multiple cancers and response to therapy in the near future.

Detection of senescence using machine learning algorithms based on nuclear features

A nuclear morphology-based machine learning algorithm for senescence detection

Nuclear morphology is a deep learning biomarker of cellular senescence

Cellular Senescence: Defining a Path Forward

Form follows function: Nuclear morphology as a quantifiable predictor of cellular senescence

Cellular senescence in cancer: from mechanisms to detection

Machine learning recognises senescence in glioblastoma and discovers senescence-inducing compounds

Discovery of senolytics using machine learning

Developing transcriptomic signatures as a biomarker of cellular senescence

SenNet recommendations for detecting senescent cells in different tissues

Recent Advances in Strategies for Imaging Detection and Intervention of Cellular Senescence

Cellular Senescence: Molecular Targets, Biomarkers, and Senolytic Drugs

SenSeqNet: A Deep Learning Framework for Cellular Senescence Detection from Protein Sequences

Simple Detection Methods for Senescent Cells: Opportunities and Challenges

Single-cell morphology encodes functional subtypes of senescence in aging human dermal fibroblasts

Senescence in cancer: Advances in detection and treatment modalities

Cellular senescence: the good, the bad and the unknown

Profiling microRNA expression during senescence and aging: mining for a diagnostic tool of senescent-cell burden

Quantitative identification of senescent cells in aging and disease

Systematic transcriptomic analysis and temporal modelling of the senescent human fibroblast

Cellular senescence in cancer: clinical detection and prognostic implications